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Abstract
Background: Major international differences in heart failure treatment have been repeatedly
described, but the reasons for these differences remain unclear. National guideline
recommendations might be a relevant factor. This study, therefore, explored variation of heart
failure guideline recommendations in Europe.
Methods:  Treatment recommendations of 14 national guidelines published after 1994 were
analyzed in relation to the heart failure treatment guideline of the European Society of Cardiology.
To test potential relations between recommendations and prescribing, national prescribing
patterns as obtained by a European study in primary care (IMPROVEMENT-HF) were related to
selected recommendations in those countries.
Results: Besides the 14 national guidelines used by primary care physicians in the countries
contacted, the European guideline was used in four countries, and separate guidelines for specialists
and primary care were available in another four countries. Two countries indicated that no
guideline was used up to 2000. Comprehensiveness of the guidelines varied with respect to length,
literature included and evidence ratings. Relevant differences in treatment recommendations were
seen only in drug classes where evidence had changed recently (β-blockers and spironolactone).
The relation between recommendation and prescribing for selected recommendations was
inconsistent among countries.
Conclusion: Differences in guideline recommendations are not sufficient to explain variation of
prescribing among countries, thus other factors must be considered.
Background
Chronic heart failure is a common disease in all devel-
oped countries, and its prevalence is likely to increase fur-
ther due to aging societies and improvement in therapies
[1]. Therefore, the interest in good quality of heart failure
management is twofold: optimal medical outcomes as
well as the efficient use of resources.
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Despite internationally available identical evidence, dif-
ferences in heart failure therapy among countries have
been repeatedly described for inpatient as well as outpa-
tient care [2-4]. In the European Improvement of Heart
Failure survey (IMPROVEMENT-HF) for instance, β-
blocker-use in primary care ranged from 10% in Turkey,
to 26% in the UK and 50% or more in Sweden and Hun-
gary. ACE-use ranged from almost 50% to 75%. Since
available evidence is translated into national guidelines in
most countries, national recommendations may differ
and accordingly contribute to such variation.
Differences among guidelines have been shown for vari-
ous diseases. While actual content varied little, the major
variation was found in the method and rigor of guideline
development as well as the comprehensiveness [5-8]. The
focus of this study is on content of published guidelines
in Europe. Firstly we assess the variation in recommenda-
tions for heart failure treatment; secondly we explore their
association with prescribing patterns in European coun-
tries as observed in the IMPROVEMENT-HF survey.
Methods
Only guidelines from European countries (Belgium,
Czech Republic, France, Germany, Great Britain, Hun-
gary, Italy, Portugal, Russia, Scotland, Spain, Sweden,
Switzerland, The Netherlands, Turkey) were considered.
Guidelines were compared to the treatment guideline of
the European Society of Cardiology (ESC) [9]. The version
of 1997 was chosen as the reference guideline in order to
relate recommendations to prescribing data from the
European IMPROVEMENT-HF survey, which was con-
ducted in 1999/2000 [3]. This study reported prescribing
data from 11062 patients treated by 2327 primary care
physicians in 14 countries.
Guidelines and recommendations for heart failure were
collected through national experts (members of the ESC
working group on heart failure or a recommended substi-
tute) and by search of websites of national cardiology
societies as well as Medline. Only guidelines produced by
national organizations or published on a national level
between 1994 and 2002 were included. Regional guide-
lines were not taken into account. For the main analysis
the original version was always used, even if updates
became available.
Two approaches were used to determine the content of
national guidelines: Firstly, national experts completed a
questionnaire about the content of the most commonly
used guideline by primary care physicians (PCPs) in their
country at the time of the IMPROVEMENT-HF study (up
to 2000). Secondly, the researcher together with a native
speaker with medical background used the original guide-
line documents to complete the questionnaire. In case of
discordance, the national expert was contacted again.
As a proxy for quality, four dimensions of formal
appraisal instruments [10,6] were used (provided infor-
mation about authors, specified target group, information
about used evidence (citations), grading of evidence).
Form and content of guidelines with different publication
years or target groups were compared. Information about
publication, dissemination and use of all existing national
heart failure treatment guideline(s) was retrieved from the
questionnaire and described.
Obtained recommendations were compared to the ESC
recommendations and grouped into one of the following
three categories: recommendations identical with the ESC
recommendation (identical); recommendations differing
from ESC (disagreement); and ESC recommendations not
included or mentioned in the particular guideline (not
specified). In case of disagreement specification was
asked.
To relate recommendations to prescribing only recom-
mendations of guidelines available before the survey were
used. If more than one guideline was published in a coun-
try, the one mostly used by GPs (Italy, Germany and NL)
was included. Prescribing data from the IMPROVEMENT-
HF survey was used. Prescribing between groups of coun-
tries with identical recommendations was compared and
the effect of recommendations on prescribing was ana-
lyzed using logistical regression (SPSS 11.0). Multivariate
analysis was performed to account for patient characteris-
tics influencing prescribing (age, sex and severity of dis-
ease (NYHA); significant at the 5% level in univariate
analysis).
Results
From 16 heart failure experts contacted, 13 replied citing
16 guidelines. Besides the European reference guideline, a
further 14 guidelines for treatment of heart failure were
included in the study (Table 1). The Scottish and the Rus-
sian documents were retrieved from the Internet and no
expert opinion was available. Belgium and Turkey
reported that no CHF-guideline had been used in their
country. In four countries (Hungary, Portugal, Switzer-
land, UK) the ESC guideline was used exclusively. More
than one guideline had been published in four countries,
different for specialists and primary care. According to
expert information, guidelines were disseminated via
publication in professional literature (14 of 16), by scien-
tific meetings (14 of 16) and Continuing Medical Educa-
tion (CME; 11 of 16). Three guidelines have been updated
along with the changes to the ESC guideline.BMC Health Services Research 2005, 5:57 http://www.biomedcentral.com/1472-6963/5/57
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Form
Presentation and comprehensiveness of the guidelines
varied (Table 1). Length along with included literature,
ranged from comprehensive publications to handouts
comprising only flowcharts. The method of development
was clearly stated in 8, evidence ratings were included in
10 guidelines. National specialist societies or physician
organizations were the authors in all but two cases. Epide-
miology was discussed in all guidelines, etiology in all but
the Italian leaflet for general practitioners. The economic
relevance of heart failure was mentioned in about half of
the documents. In 10 cases a target group of physicians
was specified in the guidelines or was defined by the pub-
lishing organization or journal, which addressed specific
groups of physicians. All guidelines specifically directed at
specialists (except the oldest, the Dutch CBO) included
more than 100 citations and gave evidence levels for their
recommendations, whereas, on the other hand, guide-
lines without evidence levels or less than 30 citations were
directed at PCPs or did not specify the target group (Table
1). Guidelines for specialists contained more detailed rec-
ommendations than the others (10% non-specified rec-
ommendations in guidelines for specialists as opposed to
24% in the others, Table 2), yet the content of included
recommendation did not differ vastly. Overall, three of
the 15 guidelines provided information on all four quality
dimensions, six did not specify either the target group or
the development procedure but all the remaining criteria.
Table 1: List and characteristics of analyzed guidelines for heart failure
Country Pub year Authors Dev. Target 
group
No. Ref Grading Epidem Etiology Econ. 
relevance
NL 1994 CBO + Specialists 0 - + + +
NL 1995 NHG + GP 191 + + + -
France 1996 Individual experts - Specialists 129 + + + +
Hungary 
Portugal CH, 
UK
1997 Task Force of European Society 
of Cardiology
+ All 
physicians*
6 9 +++ +
Italy 1997 Task force in collaboration with 
society of non-hospital-
cardiologists, SIC
+ Specialists 120 + + + -
CZ 1998 Czech Society of Cardiology GP 30 - + + -
D 1998 Medical Commission of the 
physician associations (AkdA)
+ G P 6 6 +++ -
D 1998 German Society of Cardiology, 
DGK
- Specialists 213 + + + -
Italy 1998 ANMCO (Cardiol. Society) and 
SIMG (GP-society)
- G P 0--- -
Scotland 1998 SIGN (Scottish Intercollegiate 
Guideline Network)
+N o t  
specified
2 1 1 +++ +
Sweden 1998 SOS (National Board of Health 
and Welfare)
+ All 
physicians
0-++ -
Spain 1999 Working Group for HF of the 
Spanish Soc. of Cardiology
+G P  a n d  
specialists
1 1 3 +++ +
Sweden 2000 MPA (Medical Product Agency) Physicians 
other than 
cardiologists
0+++ +
Russia 2001 Ju. N. Belenkow, Scientific 
Research Institute of Cardiology, 
Ministry of Health, Moscou
-N o t  
specified
0-++ +
CH 2002 Working group on HF of the 
Swiss society of cardiology
+N o t  
specified
2 4 +++ +
Total (n = 15) 9 9 10 10 13 13 8
+ included, - not included, GP = General Practitioner, NL: The Netherlands, CZ: Czech Republic, CH: Switzerland, D: Germany, Swe: Sweden
Dev.: method of development is outlined in the document. Target group: as specified in the GL, according to publication or as indicated by 
specialist in questionnaire.
Grading: levels of scientific evidence given with recommendations. "Quality" included specification of development, target group, evidence levels 
and literature.
* In Portugal the ESC-guideline was targeted at specialists. # This version was last updated 11/2001BMC Health Services Research 2005, 5:57 http://www.biomedcentral.com/1472-6963/5/57
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Content
Similarities
Drug therapy recommendations for diuretics, ACE-inhib-
itors and glycosides did not reveal major differences (Fig-
ure 1). Only the Dutch NHG-guideline for primary care
recommended diuretics as first drug choice prior to ACE
inhibitors. The cut-off value for the ejection fraction
below which ACE-treatment should be initiated varied
between 40% (ESC) to 25% (Russia).
Differences
The indications for β-blocker use varied (Figure 1).
Whereas 9 guidelines recommended their use for all stable
CHF patients (three excluded most severe cases, NYHA
class IV), the ESC guideline along with three others advo-
cated β-blockers only for idiopathic dilated cardiomyopa-
thy. Those were published in 1994, 1998 and 2000.
The recommendation to restrict their initiation and con-
trol to specialists was included by the majority, with an
overall range from: not to be used by GPs at all (Dutch
NHG 1994) to: by any doctor (Spain, 2000). The relation
Table 2: Overall differences in content between guidelines for different target groups
recommendations* Identical with ESC [%] Disagreement [%] Not specified [%]
Guidelines for† Specialists (n = 5) 70 19 10
other (n = 9) 63 13 24
A l l  ( n  =  1 4 ) 6 51 61 9
*Each guideline was checked for 16 recommendations and compared to the European guideline (ESC) of 1997
† see Figure 1.
Variation in recommendations included in European guidelines Figure 1
Variation in recommendations included in European guidelines. Recommendations relating to one drug are grouped; 
corresponding results (percentages of identical, different or not specified recommendations) are shown in adjacent horizontal 
bars. n = 14 national guidelines (other than the European Society of Cardiology (ESC)-guideline).
Recommendations (based on ESC guideline):
ACE–inhibitors (ACE)
a. For all symptomatic Heart Failure (HF) patients
b For all HF patients with an Ejection Fraction (EF) <40% (also if asymptomatic)
Diuretics
a Only in combination with ACE-inhibitors (if possible)
b For all HF patients with fluid retention
Glycosides:
a For HF patients with atrial fibrillation (AF): to control heart rate
b For HF patients with sinus-rhythm and NYHA III/IV: in combination with ACE and
Diuretics to improve symptoms
Beta-Blockers (BB):
a Only for patients with idiopathic dilated cardiomyopathy
b. Only to be initiated by specialists
Spironolactone:
a As additional choice in diuretic-induced hypokalemia.
b In general not in combination with ACE- inhibitors
c Only in severe HF as addition to ACE-inhibitors and diuretic (under close monitoring)
Nitrates / Vasodilators
a Combination of Nitrate and Hydralazine if ACE inhibitor is contraindicated
b Nitrates as mono-therapy for concomitant therapy of angina pectoris or acute
dyspnoea only
Dopaminergic agents (Ibopamine): a. not recommended for repeated or long term use
Anticoagulants: a. Not indicated for HF alone (only in AF or after myocardial infarction or other
indications)
Antiarrhythmics: a. in general: no indication for HF
0% 20% 40% 60% 80% 100%
identical with ESC different not specifiedBMC Health Services Research 2005, 5:57 http://www.biomedcentral.com/1472-6963/5/57
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to publication time was generally consistent: The limita-
tion to specialists was included mainly in earlier guide-
lines and the two guidelines clearly disagreeing were both
from 2000. Yet, in Switzerland the limitation was still
included in 2002.
Also recommendations for spironolactone showed differ-
ences (Figure 1): The Dutch CBO (1994) and the Italian
brochure (1997) did not mention spironolactone at all.
Before 1999 agreement about the use of spironolactone as
an additional diuretic in hypokalemia was more frequent
(5 of 10 vs. 1 of 4 after 1999). Also more frequent was the
recommendation not to combine spironolactone with
ACE. After 1999 this warning was replaced by the
recommendation to use spironolactone in addition to
ACE and other therapy in severe heart failure.
Only minor variation was found in recommendations for
other drug groups: The combination of nitrates and
hydralazine as additional symptomatic treatment choice
was only recommended by the two German guidelines.
Of the 9 guidelines addressing anticoagulation, three
specified their indication for patients with an EF < 20–
25% (D, Italy) or NYHA 3 and 4 (Russia).
Updates in guidelines
When comparing the different versions of the German,
the Dutch CBO and the ESC guideline, the emergence of
new evidence for β-blockers and spironolactone is
reflected by the order in which it is discussed in the guide-
lines: β-blockers in the old versions were the fourth or
later topic, in the new versions they were moved to second
or third. Spironolactone was no longer discussed within
the diuretics-section but separately. For other drug groups
no major changes were found. In the Dutch document the
use of tests and particularly echocardiography to establish
diagnosis was more clearly recommended.
Guidelines and prescribing
Recommendations for ACE-inhibitors did not differ
between the countries, yet prescribing ranged from 48%
in Sweden and 76% in Hungary[3]. Also glycoside-use
ranged from 24% in the UK to 45% in Italy and 55% in
Turkey.
Table 3: Actual prescribing in relation to recommendations
Recommendation Countries 
(% of total)
Year of publication 
Range (mean)
(%) Drug use 
% patients with OR (95%CI)
Spironolactone in general not to be 
given in combination with ACE
ACE + spironolactone
univariate multivariate
All countries* 10381 
(100%)
6.6
Warning (Identical) NL, Cz, F, D, Swe 
(36,5%)
1995–1998 
(1997)
5,7 0.78 
(0.66–0.91)
0.74 
(0.63–.87)
no warning/no recommendation† Remaining 
(63,5%)
1998 
(1998)
7,2 1 1
β-blockers are indicated only for 
patients with IDCM (idiopathic 
dilated cardiomyopathy)
β-blocker
All countries* 10381 
(100%)
33.8
Restricted indication (identical) Cz, H, CH, UK 
(28.6%)
1998 
(1998)
40.4 1 1
No restriction Remaining† 
(71.4%)
1995–1998 
(1997)
31.1 0.67 
(0.61–0.73)
0.69 
(0.63–0.76)
*Poland was excluded from the analysis, because no GL information was available.
†includes all countries without guideline before 2000 and guidelines without recommendation. In the case of NL and Italy, the specific guideline for 
GPs has been used.BMC Health Services Research 2005, 5:57 http://www.biomedcentral.com/1472-6963/5/57
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Where major differences in recommendations were
present (for spironolactone and β-blockers), the relation
to prescribing was inconsistent. Where recommendations
warned about the combination of spironolactone with
ACE (before 2000, average year of publication: 1997) this
drug-combination was prescribed significantly less than
where no warning was included in the guideline (Table 3).
In contrast, β-blockers were prescribed more likely if rec-
ommendations restricted their indication to the subgroup
of patients with idiopathic dilated cardiomyopathy (Table
3). Those guidelines (available before 2000) were all pub-
lished 1998 with the exception of the Dutch guidelines for
specialists from 1994; the ones without specification were
published between 1995 and 1998. Also if the Dutch and
Italian guidelines for specialists were used in the statistical
model, the same trend was found. In both cases correcting
for patient characteristics did not change the pattern
either.
Discussion
The goal of this study was to assess the degree of variation
between recommendations for heart failure treatment in
Europe as an potential factor explaining international var-
iation in prescribing. To our knowledge the content of a
wide range of European heart failure guidelines and its
relation to actual prescribing data has not been assessed
before [5].
Similar to other studies comparing guideline recommen-
dations [8,6] our results did not reveal major differences.
With the exception of one of the oldest, all guidelines rec-
ommended ACE-inhibitors as first line medication. Rec-
ommendations for diuretics and glycosides were basically
identical.
Most variance was found where the emergence of new evi-
dence induced changes in established therapy during the
study period, namely for spironolactone [11] and β-
blockers [12]. The role of spironolactone in severe heart
failure was changed by the RALES study in 1999. This is
reflected in a switch from warning about the combination
of spironolactone with ACE inhibitors in earlier guide-
lines to recommending this combination in the later ones.
The growing importance of β-blockers for CHF therapy
was reflected in a trend to widen the indication and not to
restrict its prescribing to specialists any more. However,
the respective conservative recommendation was still
included in one newer guideline (from 2000 or 2002). On
the other hand different recommendations were not
reflected in the average publication year of guidelines.
Thus, new evidence is not always taken up at the same
pace; some countries appear to be more conservative or
cautious than others.
Still, as to be expected the frequency of updates influenced
the time lag between emergence and inclusion of new evi-
dence. The two German guidelines were updated within
three years and new evidence was reflected in the changes
made. In the Netherlands the guideline for primary care
from 1995 was updated together with the 1994 guideline
for specialists in an interdisciplinary manner only in
2002. Thus, despite being early in guideline development,
this time span between updates resulted in some recom-
mendations, which were not in accordance with newer
evidence for some years.
The target group to which a guideline is directed appeared
to play a role for both, the formal scientific appearance
and the content. Guidelines for primary care physicians
included fewer citations, gave evidence levels less fre-
quently, and included fewer specific recommendations. It
has been shown, that form and credibility of the guide-
lines' authors influence their uptake [13,14]. Given the
fact, that primary care is where prescribing for heart failure
mainly takes place in most European countries [15,16]
and that primary care physicians tend to be less in accord-
ance with newer evidence than specialists [17-20], guide-
lines directed at general practitioners should be given
special attention. In our study, in six countries no specific
guideline for primary care physicians could be detected.
Thus, to adjust form and content of guidelines to primary
care physicians' needs might be one way of improving the
implementation of evidence in primary care.
By associating national recommendations with prescrib-
ing data we aimed to further explore the role of guidelines
in international variation of heart failure therapy. The
found relationship, however, appeared to be inconsistent:
On the one hand, guideline-recommendations for major
drug classes were similar while prescribing e.g. for ACE-
inhibitors differed by about 25% among countries. On
the other hand, when recommendations differed between
countries, prescribing was not always correlated. Another
example from our data for the weak link between prescrib-
ing and guideline recommendations is the Dutch case,
where despite the conservative guideline recommenda-
tions in 1999 the frequency of ACE and β-blocker pre-
scribing ranged at the European mean.
Limitations to the study
In order to better understand the relationship between
heart failure prescribing and national recommendations
in European primary care, this study focused on pub-
lished content rather than on the rigor of development of
guidelines. In view of this focus guidelines were assessed
in a explorative, descriptive manner. Instead of using one
formal guideline appraisal instrument [21] we assessed
major dimensions according to the checklists provided by
Grilli [10] and Kulig [6] to give an indication about qual-BMC Health Services Research 2005, 5:57 http://www.biomedcentral.com/1472-6963/5/57
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ity. In depth analysis of recommendations was limited to
major drug groups and therefore minor differences might
not have been considered.
Only European guidelines were included in this study, as
they were to be analyzed in connection with the prescrib-
ing data. For the same reason the European guideline of
1997 (ESC) formed the basis for the content analysis
rather than the later version of 2001. Nevertheless newer
recommendations were included and therefore changes
over time could still be detected.
In the statistical analysis, we accounted for differences in
selected patient characteristics between the compared
groups that are relevant determinants of prescribing, how-
ever other potentially relevant patient (or doctor) factors
were not included. In addition, in this cross sectional
analysis differences in time of guideline publication and
emergence of new evidence could not be accounted for.
Therefore prescribing data and its link to recommenda-
tion can only give an indication about general relations
between the two.
Further, countries can only be grouped according to pub-
lished national guidelines. This might not in all cases
reflect recommendations actually used by physicians.
Detailed information about the implementation process
[22-24] as a major aspect for a guideline's impact on pre-
scribing was beyond the scope of this study, although our
expert replies suggest roughly comparable approaches of
guideline dissemination. The range of different forms as
well as of authoring groups may have further compro-
mised comparability of acceptance and uptake.
Although recruitment procedures of practices aimed to
include comparable national populations, variations in
physician characteristics were still present. Further, even
though only primary care practices were included, there
might have been relevant differences in national organiza-
tion of care.
Conclusion
In the majority of the European countries surveyed
national heart failure treatment guidelines were available
at the time of the study. Nine of 15 guidelines included
information about at least three quality dimensions (spec-
ified authors and development, specified target group,
citations and grading of evidence), still form and compre-
hensiveness varied substantially.
Differing degrees of comprehensiveness for different user
groups suggest that increased attention to the target group
of primary care when issuing recommendations might
enhance the uptake of guidelines, bearing in mind that
CHF is treated primarily in primary care.
This study suggests that national guidelines only play a
minor role in explaining differences in heart failure ther-
apy between countries. The majority of recommendations
were similar, differences were found mainly within drug
groups where evidence has undergone recent change.
Also, in the case of distinct national recommendations,
prescribing within countries does not appear to consist-
ently follow the advice. These data emphasize the rele-
vance of country specific factors for prescribing at a
national level, one of which may be the implementation
of guideline recommendations.
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